Leading marine biotechnology company Aquapharm Biodiscovery based in Oban, Scotland, involved in the pioneering discovery and development of new pharmaceuticals, nutraceuticals and personal care products from marine microbes, has appointed Douglas Thomson to the role of commercial director and Prof Axel Kleemann as non-executive director.
Thomson draws on over 20 years of commercial experience in the pharmaceutical industry and has been active in business development roles and also in the field of vaccines.
Kleemann has years of experience working in the pharmaceutical industry, he chairs Protagen's boardof directors as well as a number of other biotech and fine chemical companies.
Aquapharm ceo and founder Dr Andrew Mearns-Spragg, said "I am extremely pleased with these two appointments and both will greatly contribute to the future growth of Aquapharm. Douglas" formidable track record in commercial development and expertise in anti-infectives will be key to our commercial development. Equally, we are all delighted to welcome Axel onto the board, where his depth of business and industry experience will be invaluable to Aquapharm in driving its commercial strategy."
